崔洁,周京敏

• 1:复旦大学附属中山医院心内科

摘要(Abstract)：

<正>心力衰竭(心衰)的治疗是近年来心血管疾病治疗的难点之一,随着慢性心力衰竭(chronic heart failure,CHF)规范化治疗的推广应用,对于经充分规范化药物治疗后仍有明显心衰症状的患者,应用铁剂治疗改善心衰的症状成为该领域的研究热点之一。本文就铁缺乏症对CHF患者的影响及近年来铁剂在CHF治疗中的应用进展作一综述。1CHF患者的贫血与铁缺乏症

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation): “十二五”国家科技支撑计划项目课题(2011BAI11B10)

作者(Author): 崔洁,周京敏

参考文献(References)：

• [1]Dunlay SM,Weston SA,Redfield MM,et al.Anemia and heart failure:a community study[J].Am J Med,2008,121(8):726-732.
• [2]He SW,Wang LX.The impact of anemia on the prognosis of chronic heart failure:a meta-analysis and systemic review[J].Congest Heart Fail,2009,15(3):123-130.
• [3]Groenveld HF,Januzzi JL,Damman K,et al.Anemia and mortality in heart failure patients:a systematic review andmeta-analysis[J].J Am Coll Cardiol,2008,52(10):818-827.
• [4]Jankowska EA,Rozentryt P,Witkowska A,et al.Iron deficiency:an ominous sign in patients with systolic chronic heart failure[J].Eur Heart J,2010,31(15):1872-1880.
• [5]Okonko DO,Mandal AK,Missouris CG,et al.Disordered iron homeostasis in chronic heart failure:prevalence,predictors,and relation to anemia,exercise capacity,and survival[J].J Am Coll Cardiol,2011,58(12):1241-1251.
• [6]Naito Y,Tsujino T,Matsumoto M,et al.Adaptive response of the heart to long-term anemia induced by iron deficiency[J].Am J Physiol Heart Circ Physiol,2009,296(3):H585-H593.
• [7]Jankowska EA,Rozentryt P,Witkowska A,et al.Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure[J].Card Fail,2011,17(11):899-906.
• [8]Efstratiadis G,Konstantinou D,Chytas I,et al.Cardio-renal anemia syndrome[J].Hippokratia,2008,12(1):11-16.
• [9]Van Craenenbroeck EM,Pelle AJ,Beckers PJ,et al.Red cell distribution width as a marker of impaired exercise tolerance in patients with chronic heart failure[J].Eur J Heart Fail,2012,14(1):54-60.
• [10]Aung N,Ling HZ,Cheng AS,et al.Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure[J].Int J Cardiol,2013.
• [11]Nanas JN,Matsouka C,Karageorgopoulos D,et al.Etiology of anemia in patients with advanced heart failure[J].J Am Coll Cardiol,2006,48(12):2485-2489.
• [12]van der Meer P,Groenveld H,Januzzi JL Jr,et al.Erythropoietin treatment in patients with Chronic Heart Failure:a meta-analysis[J].Heart,2009,95(16):1309-1314.
• [13]Jin B,Luo X,Lin H,et al.A meta-analysis of erythropoiesis-stimulating agents in anaemic patients with chronic heart failure[J].Eur J Heart Fail,2010,12(3):249-253.
• [14]Silverberg DS.The role of erythropoiesis stimulating agents and intravenous(IV)iron in the cardio renal anemia syndrome[J].Heart Fail Rev,2011,16(6):609-614.
• [15]McMurray JJ,Anand IS,Diaz R,et al.Design of the Reductionof Events with Darbepoetin alfa in Heart Failure(RED-HF):a phaseⅢ,anaemia correction,morbidity-mortality trial[J].Eur J Heart Fail,2009,11(8):795-801.
• [16]Swedberg K,Young JB,Anand IS,et al.Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure[J].N Engl J Med,2013.
• [17]Bolger AP,Bartlett FP,Penston HS,et al.Intravenous iron alone for the treatment of anemia in patients with chronic heart failure[J].J Am Coll Cardiol,2006,48(6):1225-1227.
• [18]Okonko DO,Grzeslo A,Witkowski T,et al.Effect of intrav-enous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF:a randomized,controlled,observer-blinded trial[J].J Am Coll Cardiol,2008,51(2):103-112.
• [19]Anker SD,Comin Colet J,Filippatos G,et al.Ferric carbox-ymaltose in patients with heart failure and iron deficiency[J].N Engl J Med,2009,361(25):2436-2448.
• [20]Silverberg DS,Iaina A,Schwartz D,et al.Intravenous iron in heart Failure:beyond targeting anemia[J].Curr Heart Fail Rep,2011,8(1):14-21.
• [21]Bailie GR.Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia:a review of randomized controlled trials across different indications[J].Arznei-mittelforschung,2010,60(6a):386-398.
• [22]Moore RA,Gaskell H,Rose P,et al.Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose(Ferinject)from clinical trial reports and published trial data[J].BMC Blood Disord,2011,11:4.
• [23]Jelani QU,Katz SD.Treatment of anemia in heart failure:Potential risks and benefits of intravenous iron therapy in cardiovascular disease[J].Cardiol Rev,2010,18(5):240-250.
• [24]Avni T,Leibovici L,Gafter-Gvili A.Iron supplementation for the treatment of chronic heart failure and iron deficiency:systematic review and meta-analysis[J].Eur J Heart Fail,2012,14(4):423-429.